文献速递心血管技术与安全PETCT

[18F]-氟比他班PET/CT鉴别心脏免疫球蛋白轻链型淀粉样变、转甲状腺素蛋白淀粉样变及类似病变

[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-08-05

本研究为前瞻性三臂单中心II期探索性研究,纳入40例活检证实的心脏淀粉样变患者(20例AL、20例ATTR)和20例初疑诊后诊断为非心脏淀粉样变病变患者,行[18F]-氟比他班PET/CT动态及静态显像。视觉评估显示所有亚组早期均有强烈心脏摄取,AL患者在所有静态扫描中持续高摄取,而ATTR和非心脏淀粉样变病变患者早期扫描后摄取下降。半定量评估显示AL患者SUVmean较高且整个采集期持续,提示延迟[18F]-氟比他班心脏摄取可能鉴别AL与其他情况。

要点

  • 延迟[18F]-氟比他班PET/CT心脏摄取可鉴别AL型心脏淀粉样变与ATTR或类似病变。
  • AL患者静态扫描持续高摄取,ATTR和非心脏淀粉样变早期后摄取下降。
  • AL患者早期SUVmean 5.55 vs 延迟3.50(p=NS),整个采集期持续。

关键影像表现/征象

  • 视觉定性评估显示所有亚组早期均有强烈心脏摄取。
  • AL患者在所有静态扫描中显示高且持续的心脏摄取。
  • ATTR和非CA患者在早期扫描后摄取迅速下降。

诊断标准与关键数值

  • AL患者早期SUVmean 5.55(IQR 4.00-7.43)vs 延迟SUVmean 3.50(IQR 2.32-6.10),p=NS。
  • ATTR患者早期SUVmean 2.55(IQR 1.80-2.97)vs 延迟SUVmean 1.25(IQR 0.90-1.60),p<0.001。
  • 非CA患者早期SUVmean 3.50(IQR 1.60-3.37)vs 延迟SUVmean 1.40(IQR 1.20-1.60),p<0.001。
  • 心脏与背景比值及分子体积比较结果类似。

临床应用与阅片要点

  • 延迟[18F]-氟比他班PET/CT心脏摄取可能作为无创工具用于诊断AL淀粉样变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to test the diagnostic value of [18F]-florbetaben positron emission tomography (PET) in patients with suspicion of CA.

BACKGROUND: Diagnosis of cardiac involvement in immunoglobulin light-chain-derived amyloidosis (AL) and transthyretin-related amyloidosis (ATTR), which holds major importance in risk stratification and decision making, is frequently delayed. Furthermore, although diphosphonate radiotracers allow a noninvasive diagnosis of ATTR, demonstration of cardiac amyloidosis (CA) in AL may require endomyocardial biopsy.

METHODS: Forty patients with biopsy-proven diagnoses of CA (20 ALs, 20 ATTRs) and 20 patients referred with the initial clinical suspicion and later diagnosed with non-CA pathology underwent a cardiac PET/computed tomography scan with a 60-min dynamic [18F]-florbetaben PET acquisition, and 4 10-min static scans at 5, 30, 50, and 110 min after radiotracer injection.

RESULTS: Visual qualitative assessment showed intense early cardiac uptake in all subsets. Patients with AL displayed a high, persistent cardiac uptake in all the static scans, whereas patients with ATTR and those with non-CA showed an uptake decrease soon after the early scan. Semiquantitative assessment demonstrated higher mean standardized uptake value (SUVmean) in patients with AL, sustained over the whole acquisition period (early SUVmean: 5.55; interquartile range [IQR]: 4.00 to 7.43; vs. delayed SUVmean: 3.50; IQR: 2.32 to 6.10; p = NS) compared with in patients with ATTR (early SUVmean: 2.55; IQR: 1.80 to 2.97; vs. delayed SUVmean: 1.25; IQR: 0.90 to 1.60; p < 0.001) and in patients with non-CA (early SUVmean: 3.50; IQR: 1.60 to 3.37; vs. delayed SUVmean: 1.40; IQR: 1.20 to 1.60; p < 0.001). Similar results were found comparing heart-to-background ratio and molecular volume.

CONCLUSIONS: Delayed [18F]-florbetaben cardiac uptake may discriminate CA due to AL from either ATTR or other mimicking conditions. [18F]-florbetaben PET/computed tomography may represent a promising noninvasive tool for the diagnosis of AL amyloidosis, which is still often challenging and delayed. (A Prospective Triple-Arm, Monocentric, Phase-II Explorative Study on Evaluation of Diagnostic Efficacy of the PET Tracer [18F]-Florbetaben [Neuraceq] in Patients With Cardiac Amyloidosis [FLORAMICAR2]; EudraCT number: 2017-001660-38).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. JACC Cardiovasc Imaging. 2020. PMID: 32771577. doi:10.1016/j.jcmg.2020.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。